文献速递传染病防控与疫情报告卫生政策与健康促进

秘鲁伊基托斯2020年7-8月抗SARS-CoV-2抗体血清阳性率:一项基于人群的研究

Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study.
PubMed 文献 · Lancet Glob Health · 2021-05-19

该研究在秘鲁伊基托斯采用地理分层代表性抽样,于2020年7月基线及8月随访检测IgG/IgM抗SARS-CoV-2抗体。校正抽样设计效应及检测性能后,估计基线血清阳性率为70%(95%CI 67-73),随访为66%(95%CI 62-70),新发暴露发生率2%(95%CI 1-3)。

要点

  • 伊基托斯第一波疫情后血清阳性率高达70%,为全球最高地区之一。
  • 一个月随访血清阳性率66%,新发暴露发生率仅2%。

核心结论

  • 伊基托斯在第一波疫情高峰后抗SARS-CoV-2抗体血清阳性率极高,但随后仍出现第二波疫情。

研究设计与样本

  • 基于人群的血清流行病学研究,采用地理分层代表性抽样,基线(2020年7月13-18日)和1个月随访(2020年8月13-18日)两个时间点。
  • 纳入726名符合条件者中的716名参与者(99%),覆盖40个分层(4个区、2种性别、5个年龄组)。
  • 使用COVID-19 IgG/IgM快速检测试纸(浙江东方基因生物技术有限公司,中国)检测抗SARS-CoV-2抗体。
  • 采用调查分析方法估计血清阳性率,校正抽样设计效应和检测性能特征。

主要发现

  • 校正后基线血清阳性率为70%(95%CI 67-73),1个月随访为66%(95%CI 62-70)。
  • 重测阳性率为65%(95%CI 61-68),新发暴露发生率为2%(95%CI 1-3)。

临床怎么用

  • 在高传播地区,血清阳性率调查有助于评估人群感染历史和后续传播风险。
  • 即使血清阳性率很高,仍可能因变异株出现而发生第二波疫情,需持续监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Detection of anti-SARS-CoV-2 antibodies among people at risk of infection is crucial for understanding both the past transmission of COVID-19 and vulnerability of the population to continuing transmission and, when done serially, the intensity of ongoing transmission over an interval in a community. We aimed to estimate the seroprevalence of COVID-19 in a representative population-based cohort in Iquitos, one of the regions with the highest mortality rates from COVID-19 in Peru, where a devastating number of cases occurred in March, 2020. METHODS: We did a population-based study of SARS-CoV-2 transmission in Iquitos at two timepoints: July 13-18, 2020 (baseline), and Aug 13-18, 2020 (1-month follow-up). We obtained a geographically stratified representative sample of the city population using the 2017 census data, which was updated on Jan 20, 2020. We included people who were inhabitants of Iquitos since COVID-19 was identified in Peru (March 6, 2020) or earlier. We excluded people living in institutions, people receiving any pharmacological treatment for COVID-19, people with any contraindication for phlebotomy, and health workers or individuals living with an active health worker. We tested each participant for IgG and IgM anti-SARS-CoV-2 antibodies using the COVID-19 IgG/IgM Rapid Test (Zhejiang Orient Gene Biotech, China). We used survey analysis methods to estimate seroprevalence accounting for the sampling design effect and test performance characteristics. FINDINGS: We identified 726 eligible individuals and enrolled a total of 716 participants (99%), distributed across 40 strata (four districts, two sexes, and five age groups). We excluded ten individuals who: did not have consent from a parent or legal representative (n=3), had moved to Iquitos after March 6, 2020 (n=3), were in transit (n=2), or had respiratory symptoms (n=1). After adjusting for the study sampling effects and sensitivity and specificity of the test, we estimated a seroprevalence of 70% (95% CI 67-73) at baseline and 66% (95% CI 62-70) at 1 month of follow-up, with a test-retest positivity of 65% (95% CI 61-68), and an incidence of new exposures of 2% (95% CI 1-3). We observed significant differences in the seroprevalence between age groups, with participants aged 18-29 years having lower seroprevalence than those aged younger than 12 years (prevalence ratio 0·85 [95% CI 0·73-0·98]; p=0·029). INTERPRETATION: After the first epidemic peak, Iquitos had one of the highest rates of seroprevalence of anti-SARS-CoV-2 antibodies worldwide. Nevertheless, the city experienced a second wave starting in January, 2021, probably due to the emergence of the SARS-CoV-2 P1 variant, which has shown higher transmissibility and reinfection rates. FUNDING: Dirección Regional de Salud de Loreto (DIRESA), Loreto, Peru. TRANSLATION: For the Spanish translation of the abstract see Supplementary Materials section.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Álvarez-Antonio C, Meza-Sánchez G, Calampa C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. Lancet Glob Health. 2021. PMID: 34022148. doi:10.1016/S2214-109X(21)00173-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。